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Atypical hemolytic uremic syndrome
in first trimester pregnancy successfully treated
with eculizumab
Gabriela Andries1, Michael Karass1* , Srikanth Yandrapalli1, Katherine Linder1, Delong Liu2, John Nelson2,
Rahul Pawar3 and Savneek Chugh3

Abstract
Background: Atypical hemolytic uremic syndrome is a rare disorder which is known to cause acute thrombotic
microangiopathy during pregnancy with poor maternal and fetal outcomes. Atypical hemolytic uremic syndrome
is caused mostly by dysregulation of alternative complement pathway secondary to genetic mutations. Most of the
cases reported have been in the post-partum period. We report a rare case of a patient who presents with thrombotic
microangiopathy in the first trimester of her eleventh pregnancy and was successfully treated with eculizumab.
Case presentation: A 30-year-old woman presented at 10 weeks of gestation with hypertension, hemolytic anemia,
thrombocytopenia, and acute kidney injury, consistent with thrombotic microangiopathy. She was managed initially
with daily plasmapheresis. However, her kidney function did not recover, requiring hemodialysis. ADAMTS13 activity
was later found to be within normal limit, hence diagnosis of atypical hemolytic uremic syndrome was strongly considered at that time and she was immediately treated with anti-C5 humanized monoclonal antibody (eculizumab).
The patient responded well (resolution of thrombotic microangiopathy and recovery of renal function) to eculizumab,
with continued remission after discharge and successfully delivered a healthy baby at term without any peripartum
complications.
Conclusion: Early recognition of atypical hemolytic uremic syndrome is often difficult as several other conditions
also manifest as thrombotic microangiopathy during pregnancy, causing delay in initiating appropriate treatment.
Our case suggests that treatment of atypical hemolytic uremic syndrome in early trimester of pregnancy with eculizumab results in good outcome to mother and fetus.
Keywords: Thrombotic microangiopathy (TMA), Atypical hemolytic uremic syndrome (aHUS), Eculizumab,
Pregnancy, First trimester
Background
Thrombotic microangiopathy (TMA) is a group of disorders with a common pathological pattern of injury
characterized by fibrin and/or platelet thrombi in the
microvasculature causing consumptive thrombocytopenia, hemolytic anemia and end organ damage. Diseases
causing primary TMA are divided into two broad categories: thrombotic thrombocytopenic purpura (TTP)
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and hemolytic uremic syndrome (HUS). In TTP, systemic clumping of platelets is caused by unusually large
multimers of von Willebrand factor as a consequence of
deficient ADAMTS13 activity (a von Willebrand factorcleaving metalloprotease). Hemolytic uremic syndrome
(HUS), on the other hand, is not associated with the
absence or severe reduction of ADAMTS13 activity and
has predominant renal involvement.
HUS is divided into typical (shiga-toxin mediated
or STEC) HUS and atypical HUS (aHUS) [1]. Atypical HUS occurs due to dysregulation of the alternative
complement pathway, leading to complement-mediated
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endothelial damage resulting in TMA and organ injuries.
Pregnancy has been associated with a wide spectrum of
TMA, ranging from HUS, TTP, and HELLP (hemolysis,
elevated liver enzymes, and low platelet count). Distinction among these three syndromes is often difficult as
they share similar clinical features. Establishing the right
diagnosis is very crucial for implementing the optimal
treatment strategies [2]. We present a very rare case of
a young lady who presented during the first trimester
of pregnancy with severe thrombocytopenia, hemolytic
anemia, and acute kidney injury (AKI). She was initially
suspected to have TTP, but later diagnosed with an unusually early presentation of atypical HUS with dramatic
clinical recovery and successful pregnancy outcome with
the use of eculuzimab.

Table 1 Patient’s laboratory result at initial presentation

Case report
A 30-year-old woman, presented to the hospital at
10 weeks of gestation, with nausea, vomiting, few episodes of watery non-bloody diarrhea, and dark colored
urine for the past 5 days. She had multiple abortions in
the past and was having her 11th pregnancy, all with the
same partner. Her past medical history is significant for
hereditary pancreatitis (R117 H gene mutation) requiring multiple surgeries, five miscarriages (all in the first
trimester), and self-resolving thrombocytopenia during
the last trimester of her previous viable pregnancies. She
tested negative for antiphospholipid syndrome (negative
anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, and lupus anticoagulant). She denied any bleeding or bruising symptoms including hematuria, epistaxis,
or vaginal bleeding.
She presented with a blood pressure of 156/99 mmHg,
heart rate of 80 beats/min, respiratory rate of 16 breaths/
min, oral temperature of 98.4°F, and peripheral oxygen
saturation of 97% on ambient air. Physical examination
was unremarkable, except for petechiae on the lower
and upper extremities. Initial laboratory investigations
revealed a hemoglobin level of 7.8 mg/dL, platelet count
of 15,000/mm3, presence of schistocytes on peripheral
smear, serum creatinine of 2.44 mg/dL, elevated lactate dehydrogenase (LDH) at 1847 U/L, aspartate aminotransferase (AST) 58 U/L, alanine aminotransferase
(ALT) 17 U/L, alkaline phosphatase 45 U/L, total bilirubin 1.7 mg/dL, direct bilirubin of 0.4 mg/dL, albumin
3.2 mg/dL, and haptoglobin <8 mg/dL.
Urinalysis showed 3+ proteinuria and 3+ blood with
spot urine protein-to-creatinine ratio of 5600 mg/g.
Her coagulation studies were normal with INR 0.95, PT
10.4 s, PTT 25.5 s and fibrinogen level of 311 mg/dL
(Table 1).
All viral serologies for hepatitis B and C, HIV and Parvovirus B-19 were all negative. With that presentation a

Test

Patient’s result Normal reference value

Hemoglobin (g/dL)

7.8

11.6–15

Hematocrit (%)

22.1

36–45

WBC (K/CU MM)

7.9

4.5–10.8

Platelet count (K/U MM)

15

160–410

BUN (mg/dL)

65

6–22

Creatinine (mg/dL)

2.44

0.57–1.11

LDH (U/L)

1847

125–220

AST (U/L)

58

4–35

ALT (U/L)

17

6–55

Total bilirubin (mg/dL)

1.7

0.2–1.3

Direct bilirubin (mg/dL)

0.4

0.1–0.6

Haptoglobin (mg/dL)

<8

13–281

Amylase level (U/L)

30

22–100

Lipase level (U/L)

8

8–78

Prothrombin time (s)

9.8

9.8–12

INR

0.95

Partial thromboplastin
time (s)

27.5

25–32

Fibrinogen level (mg/dL)

432

180–400

diagnosis of thrombotic microangiopathy (TMA) was
made. ADAMTS-13 activity and inhibitor assay was
sent to the Blood Center of Wisconsin to rule out TTP
and daily plasmapheresis was started since day 1 of her
hospitalization along with oral prednisone at 1 mg/kg/
day. No STEC testing was performed as the patient had
normal bowel movements. Despite daily plasmapheresis, the patient required multiple transfusions to maintain her hemoglobin levels above 8 (Fig. 1) and remained
hypertensive requiring 2 antihypertensive medications.
Her renal function continued to worsen (Fig. 2) requiring hemodialysis on the 4th day of initiating daily plasmapheresis. On hospitalization day-4, ADAMTS13
activity was reported to be normal at 129%. Diagnosis
of aHUS was strongly considered at that time and the
decision was made to discontinue plasmapheresis and
to start the patient on eculizumab at a dose of 900 mg
intravenously weekly. Complement gene mutation tests
were ordered as part of aHUS work-up (which was sent
to Genomic and Pathology Services of Washington University Medical School in St. Louis). Due to the patient’s
clinical instability, rifampin was initiated prophylactically
with meningococcal vaccination given after initiating
treatment with eculizumab. On Day-15 of hospitalization (after two doses of weekly eculizumab) laboratory
values started to improve. Her platelet count increased to
124,000/mm3 (Fig. 3), hemoglobin levels remained above
8.5 mg/dL without any transfusion (Fig. 1), and LDH
trended down to 520 U/L (Fig. 4). Her AKI was resolving
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Fig. 1 Patient’s hemoglobin trend during hospitalization and peripartum period. Patient’s hemoglobin trend during hospitalization and peripartum
period shows a mild increase in hemoglobin after starting eculizumab

with good urine output (BUN of 18 mg/dL and creatinine
2.44 mg/dL). Hemodialysis was then stopped and the
dialysis catheter was removed. She clinically improved
and remained hemodynamically stable. Patient was discharged home 18 days after admission.
Genetic analysis result came back few weeks after
her discharge, revealing that she had no pathogenic
sequence variants identified. Genes sequenced were C3,
CD46, CFB, CFH, CFI, DGKE, and THBD. Patient was

given induction dose of 900 mg intravenous (IV) eculizumab every week for 4 doses, followed by 1200 mg IV
biweekly for the rest of her pregnancy as an outpatient.
No maternal or fetal complications were reported during
the entire pregnancy and on the 36th gestational week,
she delivered a healthy baby through cesarean section
with no peri-operative complications. Around the time
of her delivery, her Hb was 10.9 mg/dL, BUN was 9 mg/
dL, creatinine of 0.52 mg/dL, and LDH of 163 U/L. She

Fig. 2 Patient’s creatinine trend during hospitalization and peripartum period. Patient’s creatinine trended down during hospitalization after starting eculizumab with a return of creatinine back to baseline in the peripartum period
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Fig. 3 Patient’s platelet count trend during hospitalization and peripartum period: Patient’s platelets showed a steady increase after the patient was
started on eculizumab

Fig. 4 Patient’s LDH trend during hospitalization and peripartum period: The LDH initially increased after the first dose of eculizumab, then steadily
decreased, with persistent low level in the peripartum period

was discharged home 3 days postpartum. She continues to receive two weekly eculizumab infusions after
her delivery, has had no TMA recurrence for more than
20 months on eculizumab therapy and with healthy baby.

Discussion
Dysregulation of the alternative complement pathway
is recognized in 60% of aHUS cases [3, 4]. Uncontrolled
activation of the terminal complement leads to the formation of C5b-9 complex (Membrane Attack Complex

or MAC), causing endothelial cell damage and leading to
the development of pro-coagulant and pro-inflammatory
states, which manifest as TMA [2]. Over 100 complement
gene mutations predisposing to aHUS have been identified. These include mutations in C3, CD46 (MCP), CFB,
CFH, CFI, CFHR1, CFHR3, CFHR4, DGKE, and THBD
leading to uncontrolled activation of alternative of complement pathway [4]. Mutations include loss-of-function
of complement regulatory proteins, polymorphisms,
hybrid gene encoding for a CHFR1/CFH fusion protein,
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and from gain-of-function mutations of C3 and CFB.
Penetrance of these mutations is estimated at 40–60%
penetrance with additional complement amplifying conditions needed for disease manifestation in predisposed
individuals [2, 3]. These include infection, certain drugs
(chemotherapeutic agents, immunotherapeutic agents,
antiplatelet agents, oral contraceptives, anti-inflammatory agents), malignancy, post-transplantation, and pregnancy [4].
Although aHUS is a complement mediated disease process, low levels of serum C3 are not specific for aHUS and
hence their testing is not of diagnostic value in this setting [5]. Normal C3 values do not exclude mutations or
antibodies against the complement system [6]. Recently,
Gavriilaki et al. [7] developed an interesting modification
of the Ham test (which is used for diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)) to rapidly diagnose aHUS and to differentiate it from other causes of
TMA. This test is based on complement-mediated apoptosis and death in glycosylphosphatidylinositol-anchored
complement regulatory proteins deficient cells. This will
have important clinical implications and also might help
in identifying patients at higher risk of developing aHUS
[6].
Genetic testing for mutations of the alternative complement pathway are very expensive, take several weeks,
and is informative in only 50–60% of the cases [7]. One
review article proposed that diagnosing aHUS in a
patient with TMA would require demonstration of AP
dysregulation biomarkers (for example, by elevation of
plasma Ba levels, C4d, and terminal complement activation UC5a/Cr, Uc5b-9/Cr), followed by reassessment
of proximal complement activation after specific treatment which targets terminal complement activation (e.g.
eculizumab). In patients with aHUS, persistent activation of proximal pathway should still occur despite the
treatment, and this can be demonstrated with an indirect Ham test. However, validation of this test in larger
cohorts will help in diagnosing aHUS early in the course
of the disease instead of waiting to rule out other causes
[8].
Our patient had laboratory evidence of TMA with anemia, thrombocytopenia, schistocytes, high LDH, and a
reduced haptoglobin level, correlating with the development of AKI. Testing for ADAMTS13 was negative and
liver enzyme tests were normal, thus ruling out TTP and
HELLP. This initial step is very important because the
management varies among different causes of TMA and
early initiation of appropriate treatment can have significant effect on morbidity and mortality. The presence of
worsening AKI pointed towards aHUS rather than TTP.
Typical HUS as alternative diagnosis was considered,
but she presented with no gastrointestinal symptoms to
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our hospital, rendered us questioning the value of Shiga
toxin-producing Escherichia coli (STEC) screening test
at that time. The fact that the patient’s condition continued to deteriorate after supportive treatment and plasma
exchange, makes typical or STEC-HUS unlikely to be the
diagnosis.
In a case series published by Fakhouri et al. [9] 21%
of aHUS cases were during pregnancy, with the highest
reported cases during the second pregnancy and about
80% of the presentations were at the time of delivery or
immediately post-partum. Complement activating conditions, such as pregnancy complications (preeclampsia
and HELLP), renal transplantation, autoimmune disease,
and certain medications have been illustrated as conditions that tend to unmask and precede onset of aHUS in
predisposed individuals [10]. Our patient presented with
aHUS in the first trimester, a very rare occurrence. This
is postulated to be related to the number of pregnancies
she had, with each pregnancy causing more robust complement activation secondary to induction of anti-HLA
antibodies when fetal cells transverse to the maternal
circulation.
It is also worth noting that our patient has a significant
medical history of hereditary pancreatitis, which could
potentially play a role in subclinical complement activation by a chronic inflammatory process. Hereditary
pancreatitis due to R 117 H mutation is a rare genetic
disorder, in which Arg-His substitution at residue 117
of trypsinogen gene causes failure to inactivate trypsin,
which in turns, results in autodigestion of the pancreas
[11].
The high morbidity and mortality of aHUS indicates
a severe and unmet medical need. Traditionally, aHUS
has been managed by various modalities including anticoagulants, immunosuppressive therapies, and plasma
exchange and/or plasma infusion; with a poor prognosis [12]. Plasma exchange or plasma infusion is generally poorly tolerated and has inconsistent results. In
patients with a CFH mutation, who developed a TMA,
22% of patients and 30% of patients, treated with plasma
exchange progressed to ESRD or death, respectively [12,
13]. The poor outcome on plasma exchange therapy is
attributed to directly activated platelets with complement
fragments deposited on platelet cell surfaces. Normalization of platelet count and LDH induced by plasma-based
therapy had no effect on elevated level of proximal and
terminal complement pathway activation, endothelial cell
activation, endothelial cell injury, ongoing coagulation
pathway activation, systemic inflammation, and ongoing
deterioration in renal function [8].
For patients who develop ESRD, kidney transplant is
pursued; however, transplant failure occurs in 67–81%
of patients with plasma infusion non-MCP mutation
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aHUS [13]. On the other hand, combined liver–kidney transplantation has been more successful than kidney transplantation alone, possibly curing aHUS [12,
13]. Unfortunately, due to the limited number of organs
available and the high risk of the procedure, it is less frequently attempted [13, 14]. Eculizumab is the first treatment to offer a highly specific complement-targeted
therapeutic option for patients with TMA.
Eculizumab is a high-affinity humanized monoclonal antibody that binds to and blocks the cleavage of
C5 into the inflammatory, prothrombotic, and lytic C5a
and C5b-9 terminal complement components, leaving
the upstream components, most notably C3a intact. By
blocking complement hyper activation and dysregulation, it reduces hemolysis, prothombotic activity, and
inflammation associated with aHUS including ESRD and
death. It is a pregnancy category C drug, safely used in
pregnant women. Limited study by Hallstensen et al. [15]
found that very low level eculizumab and eculizumabC5 complex were detected in the serum of newborns of
pregnant women treated with eculizumab, however the
newborns still have a fully functional complement activity. Few case reports and series have also demonstrated
long-term efficacy and safety of Eculizumab as first line
treatment in neonates and infants who suffered from
aHUS. Similar to our patient, neonates and infants in the
studies also showed complete recovery of the renal function after initiation of Ezulizumab [16, 17].
By inhibiting the late elements of the complement cascade system, patients are predisposed to infection by
encapsulated bacteria, including Neisseria meningitidis
[18–21]. Therefore, patients who have not been vaccinated against N. meningitidis should receive a quadrivalent meningococcal vaccine at least 2 weeks prior to the
first dose of eculizumab [22, 23]. In patients like ours
where we need to give the therapy immediately, prophylactic antibiotics can be administered till then. One retrospective study during STEC-mediated HUS outbreak in
Germany also reported simultaneous treatment with antibiotic for meningococcal prophylaxis in 98% of patients
treated with eculizumab [24, 25]. Rifampin, as one of the
antibiotic options, was proven effective at eradicating N.
meningitidis up to four weeks after treatment when compared with placebo [26, 27]. This case and the discussion
highlight the use of the monoclonal antibody, eculizumab,
as a viable option in the treatment of aHUS in pregnant
women. It also describes the pathophysiology of aHUS as
it relates to the complement pathway.

Conclusion
Pregnancy-associated atypical hemolytic syndrome is
a rare disorder, caused by dysregulation in complement
activation, and associated with very high morbidity and
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mortality. As several other conditions can also cause
TMA in pregnancy, physicians often face difficulty in
diagnosing aHUS. This is very important, as early recognition and initiation of treatment with eculizumab, an
anti-C5 therapy, has been proven to be highly effective.
Our case suggests that early treatment with eculizumab
in first trimester until the end of pregnancy was safely
tolerated by both mother and fetus, resulted in remission
and recovery of kidney function.
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